Blood B Cell and Regulatory Subset Content in Multiple Sclerosis PatientsJakob Habib1, Jiusheng Deng1, Neil Lava2, William Tyor2,3 and Jacques Galipeau1*
- *Corresponding Author:
- Jacques Galipeau
Department of Hematology and Medical Oncology
Pediatrics & Medicine, School of Medicine
Emory University, Atlanta, Georgi, USA
E-mail: [email protected]
Received date: March 24, 2015; Accepted date: April 25, 2015; Published date: May 04, 2015
Citation: Habib J, Deng J, Lava N, Tyor W, Galipeau J (2015) Blood B Cell and Regulatory Subset Content in Multiple Sclerosis Patients. J Mult Scler 2:139. doi:10.4172/2376-0389.1000139
Copyright: © 2015 Habib J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
B cell targeted therapies have been effective in slowing multiple sclerosis (MS) disease progression suggesting a direct causal link for this lymphoid subset. A small subset of B cells with regulative properties (Bregs) exists in peripheral blood, and induction of Bregs ameliorates experimental autoimmune encephalomyelitis (EAE), the murine model for MS. Therefore the frequency of B cell subsets and regulatory B cells in particular in peripheral blood of MS patients is of interest.
Methods: The phenotype and frequency of B cell subsets in peripheral blood from 32 MS patients and 34 healthy controls (HC) were examined using flow cytometry. Results: We found that there is an increase in CD19+ cell number in MS 1347 ± 159 cells/μL, (average ± SEM) compared to HC, 935 ± 129 cells/μL and no apparent deficiency in B-cells with a regulatory phenotype. In addition, we observed a loss of correlation between CD19+ B cells and total lymphocyte count in MS.
Conclusion: These findings suggest altered blood B-cell homeostasis in MS patients.